Amgen gráfico en tiempo real

Fundamentales del instrumento

Weekly Search
Weekly
Daily
Fecha Cerrar Cambio Cambio del % Apertura Alto Bajo

Últimas noticias

2025 Mar 29, 16:00

Adelanto semanal: Llegan las nóminas no agrícolas de EE. UU.: Qué deberías esperar

2025 Mar 22, 16:00

Adelanto semanal: Inversores, atentos a la inflación y PCE para el movimiento de la Fed

Forex Índices
2025 Mar 15, 16:00

Adelanto semanal: BoJ, Fed, SNB y BoE: ¿Cómo afectarán al mercado?

2025 Mar 04, 16:00

Adelanto semanal: Inflación de EE. UU. y tasas del BoC serán el foco de atención

2025 Mar 01, 16:00

Adelanto semanal: El mercado espera la decisión de tasas del BCE y los datos laborales de EE. UU.

2025 Feb 22, 16:00

Adelanto semanal: Inflación en Australia e índice de precios PCE subyacente de EE. UU.

2025 Feb 13, 16:00

Adelanto semanal: ¿Realizarán el Banco de la Reserva de Australia y el Banco de la Reserva de Nueva Zelanda movimientos de tipos inesperados?

2025 Feb 08, 16:00

Adelanto semanal: Los inversores estarán pendientes de la inflación en EE. UU.

Información

Spread

2.06

Spread (%)

0.6729 %

Apalancamiento

1:10

Interés a un día (Compra)

-0.0597 %

Interés a un día (Venta)

-0.0292 %

Divisa

USD

Horarios de los mercados

Markets closed

Lunes

13:31 - 19:59

Martes

13:31-19:59

Miércoles

13:31-19:59

Jueves

13:31-19:59

Viernes

13:31-19:59

Análisis y estadísticas

Apertura

---

Cierre anterior

---

Máximo/mínimo de 52 semanas

--- – ---

Capitalización de mercado

164895080448

Acciones en circulación

537204992

Fecha de ganancias (próxima)

1999-11-22

Rentabilidad por div.

2025-06-06

Fecha exdividendo

2025-05-16

Tasa de dividendo anual anticipado

9.52

Rendimiento de dividendo anual anticipado

0.031

GPA

7.55

Conoce más sobre este instrumento

Amgen Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Instrumentos relacionados

Activo
Vender
Comprar
Cambio del %
view_all_instruments
Trustpilot